Carboxymethyl Starch Phospholipid Complex for Colon-Targeted Drug Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Crohn's disease lack effective, long-term solutions for symptom management, with medications requiring timed delivery to the colon and facing challenges such as pH dependence and stomach dissolution, and existing technologies do not utilize inclusion complexation with phospholipids like phosphatidylcholine and phosphatidylethanolamine for targeted drug delivery.
Innovation Solution
A composition formed between an uncrosslinked carboxyl-substituted polymer and a phospholipid, such as carboxymethyl starch and phosphatidylcholine, allowing for sustained and targeted delivery of active ingredients like mesalamine, with a polysaccharide coating for controlled release in the colon, independent of pH.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If medications are coated to prevent dissolution in the stomach, then targeted delivery to the colon is improved, but the complexity of the dosage form increases
Solution Approach 1:
The patent employs a composite material system consisting of carboxymethyl starch (a modified polysaccharide) complexed with phospholipids (phosphatidylcholine or phosphatidylethanolamine). This composite structure provides both the protective coating function and the sustained release mechanism in a single integrated material system, eliminating the need for multiple separate coating layers and reducing overall dosage form complexity while maintaining reliable targeted delivery to the colon.
Solution Approach 2:
The invention utilizes pH-independent release characteristics achieved through the specific complexation between carboxymethyl starch and phospholipids. This parameter change (from pH-dependent to pH-independent release) allows the medication to maintain stable release properties across different gastrointestinal conditions without requiring complex pH-sensitive coating systems, thereby simplifying the dosage form while ensuring reliable colonic delivery.
2Reliability
If corticosteroids are used for long-term treatment, then symptom control is improved, but side effects increase
Solution Approach 1:
The patent extracts the harmful side effects associated with long-term corticosteroid use by providing an alternative sustained-release delivery system for aminosalicylates. The carboxymethyl starch-phospholipid complex enables these drugs to maintain effective therapeutic levels over extended periods without the severe side effects of corticosteroids, thereby separating symptom control efficacy from harmful side effects.
Solution Approach 2:
The sustained-release formulation performs preliminary action by maintaining steady drug levels over time, preventing the need for frequent dosing and the associated side effects of prolonged corticosteroid therapy. The complexation structure is designed in advance to provide prolonged release, allowing symptom control without the harmful effects of long-term corticosteroid exposure.
3Reliability
If antibiotics are used continuously, then infection treatment is improved, but pathogen overgrowth risk increases
Solution Approach 1:
The patent employs a biodegradable carboxymethyl starch-phospholipid complex that provides temporary, localized antibiotic delivery. This disposable-like approach delivers the necessary infection treatment locally and transiently, then degrades harmlessly, avoiding the continuous systemic exposure that leads to pathogen overgrowth. The formulation provides sufficient treatment duration to address infection while minimizing prolonged exposure risks.
4Stability of the object's composition
If crosslinked polymer is used to form the matrix, then structural stability is improved, but drug release control is reduced
Solution Approach 1:
Instead of using crosslinked polymers that provide structural stability but hinder drug release control, the patent inverts the approach by using uncrosslinked carboxymethyl starch complexed with phospholipids. This inverted structure achieves both structural integrity and superior drug release control through the specific host-guest inclusion complexation mechanism, allowing the drug to be released in a controlled manner as the complex naturally degrades without crosslinking constraints.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition enables pH-independent, controlled release of active ingredients in the colon, reducing gastric and duodenal release, and allows for modulation of drug release over time, providing effective symptom management for Crohn's disease.
Implementation Method 1
a complex formed between an uncrosslinked carboxyl substituted polymer and a lipid comprising a phospholipid
Implementation Method 2
The lipid may be an esterquat, or combinations thereof
Implementation Method 3
allowing for sustained and targeted delivery of active ingredients like mesalamine, with a polysaccharide coating for controlled release in the colon
Data Source
Figure 1
Figure 2A~2B
Figure 2C
AI summary
The present document describes a composition for sustained, targeted or sustained and targeted delivery of an active ingredient which includes a complex formed between a carboxyl substituted polymer and a lipid. The present document also describes dosage forms containing the composition, and an active ingredient, and methods of using the same for the treatment of diseases.